文献速递临床生化临床免疫

罗氏Elecsys维生素D总III检测法的双中心评估

Two-site evaluation of the Roche Elecsys Vitamin D total III assay.
PubMed 文献 · Clin Chem Lab Med · 2022-07-15

研究在两家临床实验室用844份血清样本评估罗氏Elecsys维生素D总III检测法,并与上一代试剂和LC-MS/MS比较。结果显示该方法与LC-MS/MS的偏倚达最优标准,生物素干扰阈值提高至1,200 ng/mL,但高浓度3-epi-25(OH)D3样本仍存在明显交叉反应。

要点

  • 与LC-MS/MS比较,Elecsys维生素D总III的偏倚仅该方法达到最优标准(<3.4%)。
  • 生物素干扰阈值提高至1,200 ng/mL,离群率低(0.26%)。
  • 高浓度3-epi-25(OH)D3样本中交叉反应仍明显(+73.7%)。

核心结论

  • 罗氏Elecsys维生素D总III检测法较上一代具有更高生物素干扰阈值、更宽测量范围和与LC-MS/MS更好的可比性。
  • 但对高滴度3-epi-25(OH)D3的交叉反应仍存在问题。

研究设计与样本

  • 研究纳入两家临床实验室收集的844份血清样本。
  • 评估罗氏Elecsys维生素D总III检测法,并与罗氏Elecsys维生素D总II和液相色谱串联质谱(LC-MS/MS)比较。
  • 同时评估不精密度、线性、基质效应、生物素干扰、与24,25(OH)2D3和3-epi-25(OH)D3的交叉反应及离群率。

主要发现

  • 仅LC-MS/MS与罗氏Elecsys维生素D总III之间的比较达到偏倚的最优标准(即<3.4%)。
  • 不精密度、线性和基质效应结果可接受。
  • 生物素干扰阈值提高至1,200 ng/mL,离群率低(0.26%)。
  • 在可用患者样本中与24,25(OH)2D3和3-epi-25(OH)D3的交叉反应较弱或中等。
  • 使用高浓度3-epi-25(OH)D3(富集)的SRM972a显示罗氏Elecsys维生素D总II和III检测法均有明显交叉反应(+74.7%和+73.7%)。

关键数值与推荐

  • 与LC-MS/MS比较的偏倚最优标准为<3.4%,仅Elecsys维生素D总III达到。
  • 生物素干扰阈值为1,200 ng/mL。
  • 离群率为0.26%。
  • 对SRM972a(高浓度3-epi-25(OH)D3富集)的交叉反应:Elecsys维生素D总II为+74.7%,总III为+73.7%。

临床怎么用

  • 在常规临床检测中,Elecsys维生素D总III较上一代具有更好的抗生物素干扰能力和与LC-MS/MS的可比性。
  • 对高滴度3-epi-25(OH)D3样本的检测结果需谨慎解读,可能存在明显交叉反应。

局限性

  • 高浓度3-epi-25(OH)D3交叉反应的问题在富集样本中仍存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The high request for vitamin D testing in the last decades has led manufacturers to develop assays on automated immunoassay platforms. The objective of this study was to evaluate the performance of the new Elecsys Vitamin D total III assay for the measurement of total 25(OH)D. METHODS: A total of 844 serum samples collected in two clinical laboratories were used to evaluate the new Roche Elecsys Vitamin D total III assay. Comparisons with Roche Elecsys Vitamin D total II and liquid chromatography tandem mass spectrometry (LC-MS/MS) were carried out. Additionally, assay imprecision, linearity, matrix effects, biotin interference, cross-reactivity with 24,25(OH)2D3 and 3-epi-25(OH)D3, and outlier rate were evaluated for the Elecsys Vitamin D total III assay. RESULTS: Only the comparison between LC-MS/MS and Roche Elecsys Vitamin D total III achieved the optimal specification for bias (i.e., <3.4%). Imprecision, linearity and matrix effects showed acceptable results. The biotin interference threshold was increased up to 1,200 ng/mL and the outlier rate was low (0.26%). The cross-reactivity with 24,25(OH)2D3 and 3-epi-25(OH)D3 was weak or modest in available patient samples. However, using SRM972a with a high level of 3-epi-25(OH)D3 (enriched) revealed an important cross-reactivity with both Roche Elecsys Vitamin D total II and III assays (+74.7% and +73.7%). CONCLUSIONS: In conclusion, the Roche Elecsys Vitamin D total III assay presents several advantages compared to the previous assay generation: higher biotin interference threshold, broader measuring range, and better comparability with LC-MS/MS. However, the cross-reactivity toward 3-epi-25(OH)D3 is still problematic in high titer samples.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Favresse J, Schiettecatte J, Wolff F, et al. Two-site evaluation of the Roche Elecsys Vitamin D total III assay. Clin Chem Lab Med. 2022. PMID: 35849629. doi:10.1515/cclm-2022-0177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。